Related Experiment Video

Updated: Jun 18, 2025

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.0K

Risk factors of osimertinib-related cardiotoxicity in non-small cell lung cancer

Yunlong Wang1, Xuan Deng1, Qinggui Qiu1

  • 1Department of Oncology, Jiangxi Provincial People's Hospital, The First Affiliated Hospital of Nanchang Medical College, Nanchang, China.

Frontiers in Oncology
|July 29, 2024
PubMed
Abstract

Insights

Osimertinib treatment for non-small cell lung cancer (NSCLC) carries a significant risk of cardiotoxicity. Smoking, hyperlipidemia, chemotherapy, and left chest radiotherapy are identified as key risk factors.

Area of Science:

  • Oncology
  • Cardiology
  • Pharmacology

Background:

  • Osimertinib is a targeted therapy for non-small cell lung cancer (NSCLC).
  • Cardiotoxicity is a potential adverse effect of NSCLC treatments.
  • Identifying risk factors for cardiotoxicity is crucial for patient management.

Purpose of the Study:

  • To investigate the risk factors for cardiotoxicity in patients with NSCLC treated with osimertinib.
  • To determine the incidence of cardiotoxicity in this patient population.

Main Methods:

  • A retrospective study of 268 NSCLC patients treated with osimertinib.
  • Patients were divided into cardiotoxicity and non-cardiotoxicity groups.
  • Logistic regression analysis was used to identify risk factors.

Main Results:

  • The incidence of cardiotoxicity was 21.64% (58 out of 268 patients).
  • Significant risk factors included a history of smoking (OR=2.569), hyperlipidemia (OR=3.412), combined chemotherapy (OR=2.018), and radiotherapy to the left chest (OR=1.629).

Conclusions:

  • Cardiotoxicity is a notable concern in NSCLC patients receiving osimertinib.
  • Smoking history, hyperlipidemia, concurrent chemotherapy, and left chest radiotherapy are independent risk factors for osimertinib-induced cardiotoxicity.
Keywords:
EGFR-TKIscardiotoxicitynon-small cell lung cancerosimertinibrisk factor

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

7.9K
A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish08:09

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

Published on: June 7, 2018

9.8K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
413
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
555
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
12.6K
Cancer Prevention02:59

Cancer Prevention

Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
6.1K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
152